当前位置: 首页 >> 检索结果
261. Heterogeneity in the association of genetic risk for RA and resultant RA phenotypes.
作者: Thomas R Riley.;Austin M Wheeler.;Bryant R England.;Grant W Cannon.;Brian Sauer.;Gary A Kunkel.;Katherine D Wysham.;Beth I Wallace.;Paul A Monach.;Andreas Reimold.;Gail S Kerr.;Isaac D Smith.;John Steuart Richards.;Iris Lee.;Geoffrey M Thiele.;Rui Xiao.;Scott M Damrauer.;Michael G Levin.;Michael D George.;Ted R Mikuls.;Joshua F Baker.
来源: Rheumatology (Oxford). 2026年65卷2期
The impact of the genetic risk for RA on resultant disease phenotype in RA is incompletely understood. Using individual genetic variants associated with RA and a polygenic score (PGS), we hypothesized that those with higher genetic risk for RA would demonstrate a more severe disease course.
262. Progressive interstitial lung disease associated with rheumatoid arthritis and abatacept: data from a multicentre cohort of 526 patients.
作者: Ana Serrano-Combarro.;Belén Atienza-Mateo.;Adrián Martín-Gutierrez.;Libe Ibarrola Paino.;Ivette Casafont-Solé.;Jesús Loarce-Martos.;Juan María Blanco-Madrigal.;Rafaela Ortega-Castro.;Natalia Mena-Vázquez.;Carlos Fernández-Díaz.;Javier Loricera.;Diego Ferrer-Pargada.;Santos Castañeda.;Ricardo Blanco.; .
来源: Rheumatology (Oxford). 2026年65卷2期
To identify clinical and therapeutic predictors of interstitial lung disease (ILD) progression in patients with RA treated with abatacept (ABA) in clinical practice.
263. Upper limb function impairment is independently associated with all Lupus Quality of Life (LupusQoL) domains in systemic lupus erythematosus.
作者: Ioannis Arkoumanis.;Maria Pappa.;Kyriaki Keramiotou.;Petros P Sfikakis.;Maria G Tektonidou.
来源: Rheumatology (Oxford). 2026年65卷1期
Patients with systemic lupus erythematosus (SLE) experience poor health-related quality of life (HRQoL) that is associated with disease characteristics, comorbidities and reduced physical activity. We aimed to investigate the relationship between upper limb function and HRQoL in patients with SLE.
264. Cytokine/chemokine profiles in rheumatoid arthritis patients who failed Boolean remission solely due to elevated patient global assessment.
作者: Shoichi Fukui.;Tohru Michitsuji.;Yushiro Endo.;Ayako Nishino.;Kaori Furukawa.;Toshimasa Shimizu.;Masataka Umeda.;Remi Sumiyoshi.;Tomohiro Koga.;Naoki Iwamoto.;Mami Tamai.;Tomoki Origuchi.;K A van Schie.;Yukitaka Ueki.;Nobutaka Eiraku.;Tamami Yoshitama.;Naoki Matsuoka.;Takahisa Suzuki.;Akitomo Okada.;Hiroaki Hamada.;Masahiro Ayano.;Toshihiko Hidaka.;Tomomi Tsuru.;Tom W J Huizinga.;René E M Toes.;Atsushi Kawakami.;Shin-Ya Kawashiri.
来源: Rheumatology (Oxford). 2026年65卷2期
Rheumatoid arthritis (RA) patients achieving original Boolean remission require a tender joint count ≤1, swollen joint count ≤1, C-reactive protein ≤1 mg/dl, and a patient global assessment (PGA) ≤1. Approximately 30% of patients meet the objective criteria but fail remission solely due to elevated PGA, termed 'near-remission'. The underlying mechanisms remain unclear, with debate whether persistent symptoms reflect residual inflammation or non-inflammatory factors.
266. Addressing cohort reliance in rare diseases literature: a scoping review of myositis research.
作者: Keeran Shivakumar.;Houssem Abida.;Emily Sun.;Ocean Ma.;Jessica Day.;Latika Gupta.
来源: Rheumatology (Oxford). 2026年65卷2期
This scoping review aimed to evaluate the extent and impact of duplication bias within contemporary idiopathic inflammatory myopathy (IIM) research.
267. A head-to-head comparison of TNF-α inhibitors as the first biologic treatment of rheumatoid arthritis.
作者: Amir Aamodt Kazemi.;Eirik Klami Kristianslund.;Joseph Sexton.;Karen Minde Fagerli.;Sella Aarrestad Provan.;Inge Christoffer Olsen.
来源: Rheumatology (Oxford). 2026年65卷2期
TNF-α inhibitors (TNFis) are effective biologic drugs for rheumatoid arthritis (RA), but their comparative efficacy is unclear due to limited direct comparisons. The objective of this work was to compare the efficacy of infliximab (INX), certolizumab pegol (CZP), etanercept (ETN), golimumab (GOM) and adalimumab (ADM) in achieving remission at 3 months in bio-naïve RA patients.
268. Tumor necrosis factor alpha inhibitors in Behçet's disease: indications, efficacy, and safety of two widely used agents.
作者: Rabia Deniz.;Oya Altun.;Saliha Kasapoğlu Erdil.;Fatıma Gül Gülbahçe İncesu.;Cemal Bes.
来源: Rheumatology (Oxford). 2026年65卷2期
Behçet's disease (BD) is characterized by relapsing mucocutaneous and major organ involvement. Although conventional immunosuppressants and CSs remain the mainstay of therapy, severe or refractory cases often require biologics. TNF-α inhibitors, particularly infliximab (IFX) and adalimumab (ADA), have become central to BD management. We compared the efficacy, safety, and drug retention of IFX and ADA in a real-world single-centre cohort.
269. Comment on: Eculizumab as rescue therapy in refractory anti-NXP2 dermatomyositis with digestive vasculitis and gastrointestinal perforation: report of two case: Reply.
作者: Loraine Combemale.;Alexandre-Raphael Wery.;Gérôme Bohelay.;Valentine Jacob.;Jean-Paul Duong- Van-Huyen.;Yves Allenbach.;Frédéric Caux.;Olivier Benveniste.
来源: Rheumatology (Oxford). 2026年65卷2期 270. Isolated muscular tuberculosis with secondary haemophagocytic lymphohistiocytosis.
作者: Weijin Zhang.;Guangzhou Du.;Shaoyu Zheng.;Zexuan Zhou.;Haibin Li.;Shijian Hu.;Kedi Zheng.;Jianqun Lin.;Qisheng Lin.;Barbara Ruaro.;Marco Matucci-Cerinic.;Daniel E Furst.;Yukai Wang.
来源: Lancet Rheumatol. 2026年 271. Comment on: Eculizumab as a rescue therapy in refractory anti-NXP2 dermatomyositis with digestive vasculitis and gastrointestinal perforation: report of two cases.
作者: Marie Robert.;Thomas Barba.;Emmanuel Ledoult.;Idris Boudhabhay.;Eric Hachulla.;Arnaud Hot.
来源: Rheumatology (Oxford). 2026年65卷2期 272. Relationship between spinal lesions related to axial spondyloarthritis and degenerative spinal lesions: 10-year follow-up of the DESIR cohort.
作者: Laura Pina Vegas.;Floris Alexander van Gaalen.;Miranda van Lunteren.;Damien Loeuille.;Caroline Morizot.;Esther Newsum.;Pascal Claudepierre.;Alain Saraux.;Antoine Feydy.;Monique Reijnierse.;Désirée van der Heijde.;Sofia Ramiro.
来源: Rheumatology (Oxford). 2026年65卷1期
This study aimed to investigate the relationship between spinal axial spondyloarthritis (axSpA)-related lesions and degenerative lesions (DLs) over 10 years (10Y).
273. The immune cell landscape analysed by imaging mass cytometry in the muscle of patients with inclusion body myositis associated or not with Sjögren's disease.
作者: Baptiste Quéré.;Amélie Bourhis.;Patrice Hemon.;Jacques-Olivier Pers.;Jean-Baptiste Noury.;Pascale Marcorelles.;Dewi Guellec.;Yves Allenbach.;Kuberaka Mariampillai.;Sarah Leonard-Louis.;Sébastien Sanges.;Thomas Machet.;Quentin Astouati.;Claude-Alain Maurage.;Gaetane Nocturne.;Clovis Adam.;Alain Meyer.;Beatrice Lannes.;Geoffrey Urbanski.;Anne Croue.;Valérie Devauchelle-Pensec.;Arnaud Uguen.;Divi Cornec.
来源: Rheumatology (Oxford). 2026年65卷2期
Several studies reported an association between Sjögren's disease (SjD) and inclusion body myositis (IBM). However, the potential specificities of IBM when associated with SjD have been poorly investigated. Here, we compared the muscular inflammatory infiltrates between IBM patients with or without associated SjD.
274. Greyscale, colour Doppler and oscillometric macroangiopathy indices in patients with autoinflammatory syndromes: the INFLAMMACARD cohort.
作者: Konstantinos Triantafyllias.;Anna Mandel.;Theodoros Dimitroulas.;Lorenzo Cavagna.;Christian Geber.;Rebecca Hasseli.;Alexandros Palloks.;Andreas Schwarting.
来源: Rheumatology (Oxford). 2026年65卷2期
To evaluate for the first time a combination of novel colour Doppler ultrasound (CDUS), greyscale (GSUS) and oscillometric indices of angiopathy in patients with autoinflammatory syndromes (AIS). Further, to explore the associations between these markers and patient- and disease-related characteristics, as well as traditional cardiovascular (CV) risk factors.
276. Comment on: Short and long-term outcomes of patients with pure membranous lupus nephritis compared to patients with proliferative disease: reply.
作者: Fadi Kharouf.;Qixuan Li.;Laura P Whittall Garcia.;Arenn Jauhal.;Dafna D Gladman.;Zahi Touma.
来源: Rheumatology (Oxford). 2026年65卷2期 279. Clinical predictors of mortality in critically ill systemic sclerosis patients: a 6-year retrospective cohort study.
作者: Boonyarak Wattanarat.;Chingching Foocharoen.;Anupol Panitchote.
来源: Rheumatology (Oxford). 2026年65卷2期
This study examines clinical predictors of 28-day mortality in critically ill systemic sclerosis (SSc) patients.
280. Efficacy and tolerability of switching from coated to compressed colchicine preparations in patients with Behçet's syndrome.
作者: Sena Fidan.;Sinem Nihal Esatoglu.;Yesim Ozguler.;Serdal Ugurlu.;Emire Seyahi.;Melike Melikoglu.;Izzet Fresko.;Muazzez Cigdem Oba.;Zekayi Kutlubay.;Gulen Hatemi.
来源: Rheumatology (Oxford). 2026年65卷2期
Beneficial results have been reported among patients with familial Mediterranean fever who switched from coated colchicine to compressed colchicine preparations due to inefficacy or intolerance. In this study, we aimed to assess whether this approach is also beneficial in patients with Behçet's syndrome (BS) with mucocutaneous and/or joint involvement who had an inadequate response to or were intolerant of coated colchicine preparations.
|